[HTML][HTML] Anti-Sa antibodies and antibodies against cyclic citrullinated peptide are not equivalent as predictors of severe outcomes in patients with recent-onset …

G Boire, P Cossette, AJ de Brum-Fernandes… - Arthritis research & …, 2005 - Springer
The prognostic value of two antibodies targeting citrullinated antigens, anti-Sa and anti-cyclic
citrullinated peptide (CCP), present at inclusion, was evaluated prospectively in a cohort of …

[HTML][HTML] Chondroitin sulfate efficacy versus celecoxib on knee osteoarthritis structural changes using magnetic resonance imaging: a 2-year multicentre exploratory …

…, L Bessette, F Morin, AJ de Brum-Fernandes… - Arthritis Research & …, 2016 - Springer
Background In osteoarthritis (OA) treatment, although chondroitin sulfate (CS) was found in
a number of studies using radiography to have a structure-modifying effect, to date CS use is …

Monocytes from patients with osteoarthritis display increased osteoclastogenesis and bone resorption: the In Vitro Osteoclast Differentiation in Arthritis study

…, AJ de BrumFernandes - Arthritis & …, 2013 - Wiley Online Library
Objective To compare the osteoclastogenic capacity of peripheral blood mononuclear cells (PBMCs)
from patients with osteoarthritis (OA) to that of PBMCs from self‐reported normal …

Production of Prostaglandin D2 by Human Osteoblasts and Modulation of Osteoprotegerin, RANKL, and Cellular Migration by DP and CRTH2 Receptors

…, JL Parent, AJ de BrumFernandes - Journal of Bone and …, 2005 - academic.oup.com
Human osteoblasts produce PGD 2 , which acts on the DP receptor to decrease osteoprotegerin
production and on the CRTH2 receptor to decrease RANKL expression and to induce …

[HTML][HTML] Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in …

N Carrier, A Marotta, AJ de Brum-Fernandes… - Arthritis research & …, 2016 - Springer
Background Age, C-Reactive Protein (CRP) and autoantibodies (Abs) are associated with
worse prognosis in patients with recent-onset inflammatory polyarthritis (EPA). Serum 14-3-3η …

PGD2 DP1 receptor protects brain from ischemia‐reperfusion injury

…, H Zhuang, AJ De BrumFernandes… - European Journal of …, 2007 - Wiley Online Library
Prostaglandin D 2 is the most abundant prostaglandin in the brain. It has long been described
as a modulator of the neuroinflammatory process, but little is known regarding the role of …

Assessing bone impairment in ankylosing spondylitis (AS) using the trabecular bone score (TBS) and high-resolution peripheral quantitative computed tomography …

…, B Aubry-Rozier, D Hans, AJ de Brum-Fernandes… - Bone, 2019 - Elsevier
Objectives To compare bone quality using the trabecular bone score (TBS) and bone
microarchitecture in the distal tibia using high-resolution peripheral quantitative computed …

[HTML][HTML] Serum CXC motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels

…, GJ Challener, AJ de Brum-Fernandes… - Arthritis research & …, 2014 - Springer
Introduction We hypothesized that serum levels of CXC motif chemokine 13 (CXCL13), a B-cell
chemokine, would delineate a subset of rheumatoid arthritis (RA) patients characterized …

Differential regulation of the signaling and trafficking of the two prostaglandin D2 receptors, prostanoid DP receptor and CRTH2

…, MD Rochdi, S Talbot, AJ de Brum-Fernandes… - European journal of …, 2007 - Elsevier
Prostaglandin D 2 (PGD 2 ) exerts its actions on two G protein-coupled receptors, the prostanoid
DP receptor and CRTH2 (chemoattractant homologous receptor expressed on TH2 cells…

Outcomes in recent‐onset inflammatory polyarthritis differ according to initial titers, persistence over time, and specificity of the autoantibodies

…, P Cossette, AJ de BrumFernandes… - Arthritis care & …, 2010 - Wiley Online Library
Objective. To prospectively evaluate the predictive value of initial titers and subsequent
variations of 3 rheumatoid arthritis–associated antibodies for outcomes at 30 months in patients …